IGC Appoints Medical Advisor Craig Cheifetz, M.D. to Consult on the Development of Cannabis-Based, Combination Therapies

BETHESDA, Md., May 16, 2017 -- India Globalization Capital Inc. (NYSE MKT:IGC) announces that Craig Cheifetz, M.D. has joined the company as an advisor to provide guidance on clinical trials, biotechnology, neuroscience, immunology and microbiology. 

Dr. Cheifetz is currently Regional Dean at Virginia Commonwealth University Inova Fairfax Campus and is the Medical Director of Inova VIP 360 (Northern Virginia's premier Concierge Medicine Program).  Dr. Cheifetz received his M.D. from the State University of New York College at Buffalo and trained in Internal Medicine at Georgetown University.  From 2011 to 2013, he served as the National GRMC Chairman.

“I welcome Dr. Cheifetz to the IGC advisory team and look forward to his contributions as we move forward in developing cannabis-based, combination therapies.  We remain committed to accelerating our initiatives and building a robust portfolio of compounds to address large market conditions,” states Ram Mukunda, CEO of IGC.

About IGC

India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions.  In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland.

For more information visit www.igcinc.us

Follow us on Twitter @IGCIR and Facebook.com/IGCIR/

Forward-looking Statements         

Please see forward-looking statements as discussed in detail in IGC's Form 10-K for fiscal year ended March 31, 2016, and in subsequent reports filed with the U.S. Securities and Exchange Commission.

Contact Info:
Claudia Grimaldi
301-983-0998